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BACKGROUND: Combined hormone treatments in post-menopausal women have different clinical responses on
uterus and vagina; therefore, we investigated differences in steroid signalling between various hormone therapies
in these tissues. METHODS: A total of 30 post-menopausal women scheduled for hysterectomy were distributed
into four subgroups: control-group (n5 9), Tibolone-group (n5 8); estradiol (E2)-group (n 5 7); E2 1medroxypro-
gesterone acetate (MPA)-group (n5 6). Medication was administered orally every day for 21 days prior to removal of
uterus and upper part of the vagina. Tissue RNA was isolated, and gene expression profiles were generated using
GeneChip technology and analysed by cluster analysis and significance analysis of microarrays. Apoptosis and cell
proliferation assays, as well as immunohistochemistry for hormone receptors were performed. RESULTS: 21-days
of treatment with E2, E2 1MPA or tibolone imposes clear differential gene expression profiles on endometrium
and myometrium. Treatment with E2 only results in the most pronounced effect on gene expression (up to 1493
genes differentially expressed), proliferation and apoptosis. Tibolone, potentially metabolized to both estrogenic
and progestagenic metabolites, shows some resemblance to E2 signalling in the endometrium and, in contrast,
shows significant resemblance to E2 1MPA signalling in the myometrium. In the vagina the situation is entirely
different; all three hormonal treatments result in regulation of a small number (4–73) of genes, in comparison to
signalling in endometrium and myometrium. CONCLUSION: Endometrium and myometrium differentially
respond to the hormone therapies and use completely different sets of genes to regulate similar biological processes,
while in this experiment the upper part of the vagina is hardly hormone responsive.
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Introduction
The uterus and the vagina originate from the same cotyledon:
the paramesonephric ducts (Mullerian ducts), which develop
into fallopian tubes, uterus and upper vagina (Yin and Ma,
2005). The uterus consists of a thick wall of smooth muscle
(myometrium) and an internal stroma-epithelial lining (endo-
metrium). Both functional layers of the uterus express estrogen
and progesterone receptors (ER and PR) after birth, but steroid
signalling has only been investigated in detail in the endome-
trium during the menstrual cycle (Ponnampalam et al., 2004;
Mirkin et al., 2005; Punyadeera et al., 2005). For myometrium,
molecular analyses mostly describe changes in gene expression
that occur during pregnancy and labour (Esplin et al., 2005;
Otun et al., 2005) or during development or treatment of leio-
myoma (Levens et al., 2005; Mangioni et al., 2005). The
vagina, known to respond to estrogen treatment (ET), expresses
ER and PR, and gene regulation has been studied, though not
very extensively, during development (Miyagawa et al.,
2004; Yin and Ma, 2005; Masui et al., 2006) and during meno-
pause when the vagina becomes atrophic and when local treat-
ment with estriol (Seidlova-Wuttke et al., 2006), or oral
hormone treatment is applied (Sagsoz et al., 2005).
During the first part of the menstrual cycle (follicular phase),
estrogen signalling is responsible for build-up of the endo-
metrial layer. Subsequently, progesterone levels increase
during the second half of the menstrual cycle (luteal phase)
and induce differentiation of the endometrium and thus
inhibit estrogen-induced proliferation (Talbi et al., 2006). A
decline in progesterone levels at the end of the luteal phase
(progesterone withdrawal) results in menstrual shedding.
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After the fertile age, when the ovaries cease to synthesize
estrogens and progestagens, the uterus involutes and the
vagina becomes atrophic. In addition, other positive effects
of estrogens are declining such as temperature control and
bone homeostasis. ET may solve these problems, but prolonged
or unopposed estrogen signalling is not a favourable situation
because it has been associated with an increased incidence of
hyperplasia and endometrial cancer (Horwitz and Feinstein,
1986). Therefore, when ET is used for the treatment of symp-
toms associated with menopause and osteoporosis, in women
who still have their uterus intact, estrogen signalling is counter-
acted by the addition of a progestagenic compound.
Combined hormone treatments in post-menopausal women
have quite different clinical responses on uterus and vagina.
The endometrium remains largely atrophic and the vagina is
stimulated. This indicates that the uterus and vagina, contain-
ing both ER and PR, must have differences in their signalling
pathways. In order to elucidate this, we have compared the
effects of estradiol (E2) treatment alone with those of E2 þ
medroxyprogesterone acetate (E2 þMPA) and tibolone treat-
ment on signalling pathways in the endometrium, myometrium
and vagina. Tibolone, an alternative for classical combined
hormone treatment has, besides estrogenic and progestagenic
properties, additional estrogen inactivating mechanisms in
the endometrium (Morris et al., 1999), thus preventing stimu-
lation of the endometrium. In the vagina, tibolone stimulates
the maturation index similar to ET (Morris et al., 1999).
Materials and Methods
Patient treatments
In total, 30 healthy post-menopausal women who visited our clinics
for treatment of endometrial prolapse, were included in this study.
‘Post-menopausal’ was defined as amenorrheic 1 year before screen-
ing, or amenorrheic 6 months before screening with a serum E2 con-
centration of 20 pg/ml and a serum FSH concentration of 40 IU/l
at screening. This study was designed as a controlled clinical trial. The
trial was registered with the National Institutes of Health, registry
number NCT00294463, at: http://www.clinicaltrials.gov, under the
name of: effects of Tibolone Treatment on the Endometrium. Patients
were excluded in case of histologic diagnosis of the endometrial
biopsy as proliferative, secretory or menstrual type endometrium,
endometrial metaplasia, endometrial or endocervical polyp(s), endo-
metrial hyperplasia, cancer or any other histological abnormality.
Double-layer endometrium thickness .4 mm measured by trans-
vaginal ultrasound was also an exclusion criterion. A full description
of the inclusion and exclusion criteria (Klaassens et al., 2006) and the
histological (Klaassens et al., 2006), biochemical (Verheul et al.,
2007) and molecular findings (Hanifi-Moghaddam et al., 2007) in
the endometrium were reported previously. The study groups were:
control-group (nine subjects, no hormonal treatment), Tibolone-group
(eight subjects, 2.5 mg of tibolone administered orally every day,
starting 21 days prior to surgery); E2-group (nine subjects, 2 mg E2
administered orally every day, starting 21 days prior to surgery);
E2 þMPA-group (six subjects, 2 mg E2 þ 5 mg MPA administered
orally every day, starting 21 days prior to surgery). Investigations
were conducted in accordance with the guidelines in The Declaration
of Helsinki, and the local ethics committees of the participating hos-
pitals approved the study protocol. Informed consent was obtained
from all participants in the study.
Isolation of tissue, RNA isolation and gene expression profiling
For the endometrium, this methodology has been described (Hanifi-
Moghaddam et al., 2007). In short, after hysterectomy, part of the
uterus and the upper part of the vagina were dissected and tissue
was snap-frozen. Cryostat sections (5 mm) of 100% pure endometrial
and myometrial tissue, or vaginal submucosal/mucosa tissue, were
homogenized by sonography and RNAwas isolated using Trizol (Invi-
trogen, Life Technologies, Philadelphia, PA, USA). Purity of the
tissues in the cryostat sections was assessed by microscopic evaluation
of each first and last section in batches of ten. This stringent quality
control has resulted in the loss of some tissues for further analysis
(the exact tissues used in the current analysis are indicated at the
top of Fig. 1). About 1 mg of total RNA was used to prepare antisense
biotinylated RNA (www.affymetrix.com). The level and quality of
complementary RNA (cRNA) was measured on the Agilent 2100
Bioanalyzer (Agilent, Palo Alto, CA, USA). The cRNA was fragmen-
ted with the GeneChip Sample Cleanup Module (Affymetrix, Santa
Clara, CA, USA). Hybridization to Affymetrix U133plus2 GeneChips
(54614 probe sets, representing 47 000 transcripts), staining,
washing and scanning procedures were carried out as described
(Affymetrix).
Data analysis
Data were normalized according to the quantile method. After normal-
ization, the intensity values below 30 were set at 30, since our method
reliably identifies samples with an average intensity value of 30 or
more but does not reliably discriminate values between 0 and 30.
Cluster analysis
For each probe set, the geometrical mean of the hybridization intensi-
ties to that probe set in all endometrial, myometrial and vaginal
samples was calculated. The level of expression of each probe set in
every sample was determined relative to this geometrical mean and
logarithmically transformed (on a base 2 scale). Genes whose level
of expression differed at least 3-fold, in at least one sample, from
the geometrical means of all treated endometrial, myometrial and
vaginal samples (reflecting up- or down-regulation) were selected
for the initial unsupervised cluster analysis using the visualization
tool of Omniviz (Ominviz, Maynard, MA, USA) (version 3.8).
SAM analysis
We used significance analysis of microarrays (SAM) (Tusher et al.,
2001), implemented in Omniviz to determine genes with significantly
differential expression between the treatment groups for all three
tissues. SAM is a statistical method for identifying differentially
expressed genes while controlling the overall false discovery rate
(FDR). FDR is the percentage of genes identified by chance. We
have chosen the settings for this analysis in such a way that the total
number of falsely identified differential expressed genes for each
tissue was 1.
Functional and biological classification of genes
All significantly differentially regulated genes were classified in
predefined biological function-categories. The complete GO-classifi-
cation data on the regulated genes in endometrium and myometrium
can be reviewed at: http://www2.eur.nl/fgg/rede/hanifi_moghaddam.
After reviewing this distribution of regulated genes, three significantly
regulated biological functions were selected for a more detailed analy-
sis: cell death, cell cycle and signal transduction.
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Real-time quantitative PCR of vaginal parameters
Real-time quantitative PCR (qPCR) (Deng et al., 2003) was per-
formed on two selected vaginal genes: kRT2A and GREB1. The
sequences of primers and probes used in this study are available
upon request.
Immunohistochemistry and terminal deoxynucleotidyl
transferase-mediated dUTP nick end labelling assay
Ki67 (marker of proliferation), ERa, PR (A and B) and androgen
receptor (AR) staining was performed on 3 mm uterus tissue sections
as described by Klaassens et al. (2006). Glycogen production was
measured after Periodic Acid Schiff staining (Claver et al., 1984).
Apoptosis was assessed using the terminal deoxynucleotidyl transfer-
ase (TdT)-mediated dUTP nick end labelling (TUNEL) was per-
formed as described by de Vries et al. (2005) and adapted by us.
Briefly, 3 mm paraffin embedded tissues sections were deparaffinized
in xylene, rehydrated and washed in phosphate-buffered saline (PBS).
The slides were heated in a microwave oven (two times 4 min at
700 W) in 0.01 M citrate buffer pH 6.0. After cooling and rinsing in
milliQ water, endogenous peroxidases were quenched by a 5-min
incubation in 2% H2O2 in PBS. Slides were then preincubated for
5 min in TdT-buffer (Promega, Madison, WI, USA) at 378C and
incubated for 1 h at 378C in TdT-buffer containing 0.01 mM
Biotin-16-dUTP (Boehringer Mannheim) and 0.3 U/ml TdT-enzyme
(Promega). Slides were incubated in stop/wash buffer (Promega)
for 15 min, followed by StreptABComplex (DAKO, Glostrup,
Denmark), according to the manufacturer’s protocol. Staining was
developed with diaminobenzidine/concentrated metal complex
(Pierce, Rockford, IL, USA) and counterstaining was carried out
with haematoxylin. Evaluation of the Ki67 and apoptosis staining
was performed with a computer-assisted imaging system Image J
1.32j (Wayne Rasband, National Institutes of Health, USA). Any
nuclear staining regardless of intensity was considered positive. Posi-
tive nuclei were counted in one field of vision at 10 magnification.
Scoring was defined as the total number of positive nuclear cells per
1 mm2 of epithelium, stroma or myometrium. Statistical analysis
was performed using the Student’s t-test (two-sided). P, 0.05 was
considered to be statistically significant. Results are expressed as
mean+SEM.
Results
Earlier work performed by our group describes the histological,
molecular and biochemical response of the endometrium to
3-week tibolone, E2 or E2 þMPA treatment compared with
non-treated controls (Klaassens et al., 2006; Hanifi-Moghaddam
Figure 1: Unsupervised cluster analysis of differentially expressed genes between endometrial (End), myometrial (Myo) and vaginal (Vag) gene
expression profiles
Those genes whose level of expression differed at least 3-fold, in at least one sample, from the geometric means of all treated endometrial, myo-
metrial and vaginal samples (reflecting up- or down-regulation) were selected for this cluster analysis. In total, 9519 probesets, representing
6000 genes, were used. Unsupervised clustering was performed using the visualization tool of Omniviz (version 3.8). At the top of the
figure the treatments [control (Con), E2 treatment alone, E2 þMPA and T21 (tibolone)] and tissues followed by the individual patient
numbers are indicated. At the bottom of the figure the main clusters and subclusters are indicated. Red indicates genes with a higher expression
relative to the geometrical means; blue indicates genes with a lower expression relative to the geometric means
Hanifi-Moghaddam et al.
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et al., 2007; Verheul et al., 2007) (hormone levels of individual
patients are posted at: http://www2.eur.nl/fgg/rede/hanifi_-
moghaddam). Here, the endometrial gene expression data
(Hanifi-Moghaddam et al., 2007) are reanalysed together
with array data obtained from myometrial and (upper)
vaginal tissues from the same patients. All raw array data
were normalized together and SAM analysis was performed
to find significantly differentially regulated genes.
Unsupervised cluster analysis
In total, 9519 probe sets (representing 6000 different known
genes) were identified that displayed at least a 3-fold change in
expression in one or more patient samples relative to the geo-
metrical means of all samples. Because of large differences
between the tissues, this methodology primarily resulted in
the identification of genes that were differentially regulated
between endometrium, myometrium and vagina. Not surpris-
ingly, cluster analysis revealed the formation of three main
clusters: a vaginal sample cluster, an endometrial sample
cluster and a myometrial sample cluster (Fig. 1).
Upon reviewing these three clusters more carefully, the
endometrial cluster separated in three subclusters: one contain-
ing endometrial profiles only from control patients, another
containing endometrial profiles from control and E2 þMPA
treated patients, and a third containing endometrial profiles
from tibolone and E2 treated patients. These results were in
accordance with our earlier findings (Hanifi-Moghaddam
et al., 2007).
Within the myometrial cluster there is a subdivision in two
subclusters. There is a subcluster containing myometrial pro-
files from all control patients together with three tibolone and
two E2 þMPA treated patients, whereas the other subcluster
contains all profiles from E2 treated patients and the remainder
of the profiles from tibolone and E2 þMPA treated patients.
For the vaginal profiles subclusters can also be recognized.
These subclusters, however, do not separate on the basis of
different treatments, but presumably on the basis of other,
unknown differences between patients, indicating that 21-day
treatment with E2, E2 þMPA and tibolone does not have a
specific impact on vaginal gene expression.
SAM analysis
SAM assigns a gene as significantly differentially expressed if
the average expression of that gene in a treatment group signifi-
cantly differs from another treatment group or from a control
group (these data can be reviewed at: http://www2.eur.nl/
fgg/rede/hanifi_moghaddam). In Table I, SAM analyses are
summarized showing the number of significantly differentially
expressed genes between the treatments or between treatments
and controls. A number of interesting observations need to be
mentioned.
First, both in the endometrium and in the myometrium E2
only treatment has the highest impact on the gene expression
profiles, whereas very few genes (16) are regulated in the
vagina by E2.
Secondly, when we compare tibolone signalling to E2 þ
MPA signalling in the endometrium, 326 genes are found to
be differentially regulated between these two treatment
groups. This indicates a significant difference in signalling in
the endometrium between these two hormone therapies.
However, when we perform the same comparison in the myo-
metrium, only four genes are found to be differently regulated,
indicating that tibolone signalling is remarkably similar to
E2 þMPA signalling in the myometrium.
Third, treatment-induced signalling in vaginal tissue is very
limited compared with signalling in the endometrium and myo-
metrium, indicating that the upper part of the vagina, in this
relatively short-term experiment, is not very hormone
sensitive.
Biological functions in the vagina
To verify that the upper vagina, despite its reduced responsive-
ness, could potentially respond to the hormonal treatments, we
have evaluated the presence of ERa, PR (A and B) and AR and
compared the results with those in the endometrium and myo-
metrium. In vagina, clear staining of both PR and ERa was
observed; AR staining, however, was less clear (Fig. 2). In
the endometrium, staining of ERa and PR was very obvious
(as shown previously (Klaassens et al., 2006)) and is in line
with the estrogen and progesterone responsiveness of this
tissue. The myometrium also contains considerable amounts
of ER and the PR. The AR expression in the endometrium
and myometrium, however, is low.
The presence of both ER and PR in the upper vagina is not in
line with the low gene signalling in the vagina after the hormo-
nal treatments. Therefore, we have evaluated the vaginal
tissues for glycogen production and epithelial thickness. Gly-
cogen production was not enhanced by any of the treatments
and vagina-epithelial thickness was also not changed by the
21-day treatments (data not shown). Furthermore, real-time
Table I. Number of significantly differentially expressed genes between the different treatments [control (Con), E2 treatment alone, E2 þMPA) and Tib
(tibolone)] in endometrium, myometrium and vagina.
E2/Con E2 þMPA/Con Tib/Con E2 þMPA/E2 Tib/E2 Tib/E2 þMPA
Endometrium 1493 404 328 685 257 326
Myometrium 1047 257 257 325 192 4
Vagina 16 73 4 16 29 45
Using SAM (Tusher et al., 2001), implemented in Omniviz (version 3.8), the number of differentially expressed genes between two treatment groups, mentioned
at the top of the figure, in one tissue was calculated. SAM is a statistical method for identifying differentially expressed genes while controlling the overall FDR.
FDR is the percentage of genes identified by chance. We have chosen the settings for this analysis in such a way that the total number of falsely identified
differentially expressed genes in a tissue was less than one. With P, 0.00029, for the endometrial analysis in total 3493 differentially expressed genes were
found, for the myometrium 2082 differentially expressed genes were found with P, 0.00048 and for the vagina, 183 differentially expressed genes were found
with P, 0.0055.
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qPCR was performed on two genes observed to be regulated by
E2, E2 þMPA and tibolone treatment in the vagina: for
KRT2A as well as GREB1, up-regulation by the three treat-
ments could readily be confirmed (Fig. 3).
Biological classification of genes in endometrium
and myometrium
Here, we will further refine the signalling analysis at the level
of regulation of predefined biological processes using various
databases. Furthermore, because treatment-induced signalling
in the upper vagina was found to be very limited, we will con-
centrate our analysis on the endometrium and myometrium.
All significantly differentially regulated genes were classi-
fied in predefined biological function-categories. After review-
ing this distribution of regulated genes, three significantly
regulated biological functions were selected for a more detailed
analysis, cell death, cell cycle and signal transduction.
In Table II, data are presented on ‘cell death’, ‘cell cycle’
and ‘signal transduction’. From Table II, it becomes clear
that E2 only treatment by far has the highest impact on gene
expression in the endometrium as well as in the myometrium.
Furthermore, reviewing the overlap in genes between endome-
trium and myometrium, the overlap turns out to be very small.
In other words, the endometrium and myometrium use comple-
tely different sets of genes to regulate similar biological pro-
cesses. Reviewing the actual numbers of genes, it is clear
that E2 regulation of ‘cell cycle’ genes is much higher in the
endometrium than in the myometrium, in contrast to ‘cell
death’ and ‘signal transduction’.
The question now becomes whether these findings actually
have a biological meaning. Therefore, proliferation was
assessed using Ki67 staining as a marker, and cell death (apop-
tosis) was assessed using the TUNEL assay. The results of the
endometrium have been published previously (Klaassens et al.,
2006; Hanifi-Moghaddam et al., 2007) and are here compared
with those of the myometrium. Figure 4 shows that prolifer-
ation in the endometrium is far more pronounced than in the
myometrium. Furthermore, in both tissues E2 only treatment
has the highest impact on proliferation.
Comparing the effects of tibolone with E2 þMPA, it was
observed that in the myometrium these two hormone therapy
drugs have a similar stimulatory effect on proliferation,
whereas in the endometrium there are differences: both prep-
arations stimulate proliferation of stromal cells while only
E2 þMPA inhibits proliferation of glandular cells, compared
Figure 2: Immunohistochemical staining for ERa, PRA and PRB and AR in endometrial, myometrial and vaginal tissue after no treatment
(control), and treatment with E2, E2 þMPA or tibolone
Representative images are shown for all different stainings and all treatment groups. Magnification is 200-fold
Figure 3: Real-time qPCR verification of upregulation of KRT2A
and GREB1 in vaginal tissues. Real-time qPCR was performed on
all vaginal RNA samples and was corrected for b-actin expression
in the same samples
In the direction of the Y-axes, the Log2 ratio of the level of expression
relative to control is indicated, on the X-axes the findings in the indi-
vidual patient-tissues in the different treatment groups
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with controls. It is clear from the TUNEL-assay data that when-
ever proliferation is increased, apoptosis is also stimulated.
Furthermore, since the number of positive staining cells is
low, SEMs are high and small differences between the treat-
ments can not be identified.
Discussion
The human endometrium and myometrium are both clearly
estrogen-responsive tissues. For the endometrium this is not a
new finding (Klaassens et al., 2006; Hanifi-Moghaddam
et al., 2007), but for the myometrium, the large number of
estrogen-regulated genes is an interesting new observation. In
the endometrium, as expected, the estrogenic response is effec-
tively counterbalanced by the addition of a progestagenic
compound (MPA) and, interestingly, in the myometrium pro-
gesterone also readily counterbalances the actions of estrogen.
Tibolone, from which both estrogenic as well as progestagenic
metabolites can be formed, also shows a progestagenic coun-
terbalance of its estrogenic properties in endometrium as well
as myometrium although there are differences between the
two tissues.
Upon a more careful examination of the effects of the differ-
ent treatments, it becomes clear that tibolone treatment of the
endometrium results in a gene expression profile which shows
more resemblance to the E2 induced endometrial expression
profile than to the E2 þMPA induced endometrial expression
profile. For the myometrium, the situation is different: here
the gene expression profile induced after tibolone treatment is
more similar to the profile after E2 þMPA treatment and
quite distinct from the E2-induced myometrial expression
profile. This observation is strengthened when myometrial
tibolone- and E2 þMPA-treatments are directly compared:
there are only four genes differently regulated by the two treat-
ments. The observation that tibolone behaves in a more
estrogen-like manner in the endometrium than in the myome-
trium under the current circumstances, illustrates its tissue-
selective modulatory properties (Reed and Kloosterboer, 2004).
More puzzling are the data obtained with the upper vagina.
In the current experimental setup, the vagina is not responding
very profoundly to stimulation with estrogens, estrogens com-
bined with progestagens or tibolone. Literature is very clear
about this: the human vagina expresses ERs (Schwartz, 2000)
and is highly responsive to estrogen-fluctuations (Utian et al.,
Table II. Biological classification of significantly differentially expressed genes in endometrium and myometrium by functional category.
Endometrium Myometrium Overlapping genes
Endo–Myo
E2 E2 þMPA Tib E2 E2 þMPA Tib
Cell death 32 3 5 26 8 9 2
Cell cycle 108 10 20 37 9 5 1
Signal transduction 159 36 40 133 31 36 4
Genes showing significant differential expression relative to control identified by SAM were classified into the biological processes ‘cell death’, ‘cell cycle’ and
‘signal transduction’ using the Panther database (panther.appliedbiosystems.com). To the right of the table the number of genes shared between endometrium
and myometrium in the regulation of a particular process are indicated.
Figure 4: Proliferation and apoptosis in endometrium and myometrium
Proliferation was measured using Ki67 staining and apoptosis was measured using the TUNEL assay. For the endometrium two different compart-
ments were assessed: glandular epithelium (open bars) and stroma (black bars). The following number of patients was included in each group:
control, n ¼ 6; tibolone, n ¼ 5; E2, n ¼ 6; E2 þMPA, n ¼ 5. Averages were calculated +SEM, and significance was measured using student
t-tests: *P, 0.05 in comparison to control. The data on Ki67 staining in the endometrium were taken from our earlier work (Klaassens et al., 2006)
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2001; Gorodeski, 2005; Gorodeski et al., 2005; Johnson et al.,
2005; Utian et al., 2005; Farage and Maibach, 2006). Our data
only show regulation of a limited number of genes but among
these genes we could identify some that have been reported in
literature as regulated by estrogens: iGF-1 (Gielen et al., 2005)
GABRP (Symmans et al., 2005), LEPR (Bryzgalova et al.,
2006), SFRP2 (Hayashi and Spencer, 2006), CYP3A5 (Wil-
liams et al., 2004), S100P (Schor et al., 2006), MUC4
(Gollub et al., 1995), C3 (Puy et al., 1993), GREB1 (Rae
et al., 2005) and ANXA1 (Castro-Caldas et al., 2001). Further-
more, real-time qPCR could indeed confirm regulation of two
chosen genes (KRT2A and GREB1). In conclusion, there is a
response of the vagina to the different treatments, the magni-
tude of the response, however, is limited.
There are a number of possible reasons for the reduced
response observed in the vagina under the current treatment con-
ditions. First, the current treatment is only for 21 days, while in
literature almost all data are collected at three or more months
after start of treatment. Secondly, here we used hormone
therapy drugs administered orally while most reports in literature
are on estrogens, which are administered locally (Suckling et al.,
2006). Local estrogens are reported to work much faster than
systemic estrogens (Palacios et al., 2005). It should be men-
tioned here that we do measure increased estrogen levels in
the upper vagina of these women with E2 or E2 þMPA treat-
ment (Verheul et al., 2007). Third, women treated in the exper-
iments described here had been post-menopausal for, on
average, 10 years and Bachmann (2005) and Gorodeski (2005)
suggest that the potency of post-menopausal vaginal cells to
respond to estrogen-treatment is significantly reduced in post-
menopausal women with permanent estrogen depletion.
In summary, 21-days of treatment of post-menopausal women
with E2, E2 þMPA or tibolone imposes clear differential gene
expression profiles on the endometrium andmyometrium. Treat-
ment with only E2 results in the most pronounced effect on gene
expression, proliferation and apoptosis, both in endometrium and
myometrium. Tibolone, potentially metabolized to both estro-
genic and progestagenic metabolites, shares some resemblance
to E2 signalling in the endometirum and, in contrast, significant
resemblance to E2 þMPA signalling in the myometrium.
In the vagina the situation is entirely different; all three hor-
monal treatments result in regulation of some genes, but the
numbers are small in comparison to signalling in endometrium
and myometrium. Possibly, the short duration of treatment, the
fact that the drugs were administrated orally or the fact that
most women had been post-menopausal for many years is at
the basis of this finding.
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